Skip to content

Study · Animal study (in vivo) · mouse · 2016

2 results

Genetic and Pharmacological Inhibition of TREM-1 Limits the Development of Experimental Atherosclerosis.

Joffre J, Potteaux S, Zeboudj L, Loyer X, Boufenzer A, Laurans L, Esposito B, Vandestienne M, de Jager SC, Hénique C, Zlatanova I, Taleb S and 5 more

Show all authors

Bruneval P, Tedgui A, Mallat Z, Gibot S, Ait-Oufella H

Journal of the American College of Cardiology1 Dec 2016Cited by 89 (Europe PMC)

PMID28007141 (opens in a new tab)DOI10.1016/j.jacc.2016.10.015 (opens in a new tab)PepBankPUB-28007141
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In ApoE-deficient mice, LR12 significantly reduced atherosclerosis development throughout the vascular tree.

    In plain wordsIn mice lacking ApoE, LR12 significantly reduced atherosclerosis development throughout the blood vessels.

    Peptide
    Nangibotide
    Outcome
    DecreaseAtherosclerosis development
    Study

    mousen: not reported in source

    ApoE-deficient mice
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Genetic invalidation of Trem-1 in ApoE-/-/Trem-1-/- mice or pharmacological blockade of Trem-1 in ApoE-/- mice using LR-12 peptide also significantly reduced the development of atherosclerosis throughout the vascular tree, and lessened plaque inflammation.
    1 context sentence
    Summary · context
    After genetically invalidating Trem-1 in chimeric Ldlr-/-Trem-1-/- mice and double knockout ApoE-/-Trem-1-/- mice, we pharmacologically inhibited Trem-1 using LR12 peptide.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In ApoE-deficient mice, LR12 lessened plaque inflammation.

    In plain wordsIn mice lacking ApoE, LR12 reduced plaque inflammation.

    Peptide
    Nangibotide
    Outcome
    DecreasePlaque inflammation
    Study

    mousen: not reported in source

    ApoE-deficient mice
    Outcome group
    Inflammation markers · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Genetic invalidation of Trem-1 in ApoE-/-/Trem-1-/- mice or pharmacological blockade of Trem-1 in ApoE-/- mice using LR-12 peptide also significantly reduced the development of atherosclerosis throughout the vascular tree, and lessened plaque inflammation.
    1 context sentence
    Summary · context
    After genetically invalidating Trem-1 in chimeric Ldlr-/-Trem-1-/- mice and double knockout ApoE-/-Trem-1-/- mice, we pharmacologically inhibited Trem-1 using LR12 peptide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.